Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far and remember, there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …

Express Scripts (ESRX), one of the largest U.S. prescription benefit managers, will cover new migraine drugs from Eli Lilly (LLY) and Amgen (AMGN), but is excluding a rival medication made by Teva Pharmaceutical (TEVA) after price negotiations with all three manufacturers, Reuters reports. The decision represents a setback for Teva, which is in the midst of a corporate restructuring and hoped to capture a sizable stake of the multibillion-dollar migraine market. Express Scripts is also taking steps to limit use to the patients it says are most likely to benefit from the new Amgen and Lilly migraine drugs.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!